<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04509050</url>
  </required_header>
  <id_info>
    <org_study_id>BEGIN-OB-19</org_study_id>
    <nct_id>NCT04509050</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Biological &amp; Clinical Effects of Significantly Corrected CFTR Function in Infants &amp; Young Children</brief_title>
  <acronym>BEGIN</acronym>
  <official_title>A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function in Infants and Young Children (BEGIN Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sonya Heltshe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-part, multi-center, prospective longitudinal, exploratory study of highly&#xD;
      effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their&#xD;
      impact on children with cystic fibrosis (CF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-part, multi-center, prospective longitudinal, exploratory study of highly&#xD;
      effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their&#xD;
      impact in children with cystic fibrosis (CF) on endocrine growth factors and height,&#xD;
      gastrointestinal function and gut microbiome, lung function and respiratory microbiome, liver&#xD;
      and pancreatic function, sweat chloride, inflammatory markers, and bone health.&#xD;
&#xD;
      Total duration of the study is expected to be 6 years. Part A will be a prospective&#xD;
      cross-sequential study to describe the natural history of hormonal growth factors in early&#xD;
      childhood and assess the feasibility of additional measurements. In Part A, subjects will&#xD;
      have up to 6 visits over a period of up to 3 years.&#xD;
&#xD;
      Part B will be a prospective longitudinal study to observe the effects of administration of&#xD;
      either ivacaftor or elexacaftor/tezacaftor/ivacaftor (elex/tez/iva) on growth. In Part B,&#xD;
      subjects will have one &quot;before ivacaftor or elex/tez/iva&quot; visit within 30 days before&#xD;
      initiation of the therapy and five &quot;after ivacaftor or elex/tez/iva&quot; visits over a 24-month&#xD;
      follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Part A Primary Outcome Measure: Change in weight-for-age z-scores</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Weight-for-age z-scores over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A Primary Outcome Measure: Change in height-for-age z-scores</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Height-for-age z-scores over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B Primary Outcome Measure: Change in weight-for-age z-scores</measure>
    <time_frame>1, 3, 6, 12, and 24 months</time_frame>
    <description>Change in weight-for-age z-scores from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B Primary Outcome Measure: Change in height-for-age z-scores</measure>
    <time_frame>1, 3, 6, 12, and 24 months</time_frame>
    <description>Change in height-for-age z-scores from baseline</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <description>Children with CF not on ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <description>Children with CF planning to start ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy. Participants from the Part A cohort of this study may enroll into the Part B cohort if they become eligible for these CFTR modulator therapies and plan to start them.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivacaftor or elexacaftor/tezacaftor/ivacaftor</intervention_name>
    <description>In Part B, approved CFTR modulator as prescribed at the discretion of the treating physician -not dictated by the BEGIN investigators</description>
    <arm_group_label>Part B</arm_group_label>
    <other_name>Kalydeco or Trikafta</other_name>
    <other_name>Vertex (VX)-770 or VX-445/VX-661/VX-770</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, Plasma, Buffy Coat, Urine, Stool, oropharyngeal (OP) swab, Bronchoalveolar lavage&#xD;
      (BAL)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Part A - children with confirmed diagnosis of cystic fibrosis who are less than 5 years of&#xD;
        age and not on ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy&#xD;
&#xD;
        Part B - children with confirmed diagnosis of cystic fibrosis who are less than 6 years of&#xD;
        age (or participated in Part A of the study) with an intention to start ivacaftor or&#xD;
        elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Part A:&#xD;
&#xD;
               -  Less than 5 years of age at the first study visit.&#xD;
&#xD;
               -  Documentation of a CF diagnosis.&#xD;
&#xD;
        Part B:&#xD;
&#xD;
          -  Participated in Part A OR less than 6 years of age at the first study visit.&#xD;
&#xD;
          -  Documentation of a CF diagnosis.&#xD;
&#xD;
          -  CFTR mutations consistent with FDA labeled indication of highly effective modulator&#xD;
             therapy (ivacaftor or elexacaftor/tezacaftor/ivacaftor).&#xD;
&#xD;
          -  Physician intent to prescribe ivacaftor or elexacaftor/tezacaftor/ivacaftor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Part A and Part B:&#xD;
&#xD;
        Use of an investigational drug within 28 days prior to and including the first study visit.&#xD;
&#xD;
        Use of ivacaftor or elexacaftor/tezacaftor/ivacaftor within the 180 days prior to and&#xD;
        including the first study visit.&#xD;
&#xD;
        Use of chronic oral corticosteroids within the 28 days prior to and including the first&#xD;
        study visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonnie Ramsey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucas Hoffman, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington/Seattle Children's</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Stalvey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachael Buckingham</last_name>
    <phone>206-884-7517</phone>
    <email>rachael.buckingham@seattlechildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Rogers</last_name>
    <phone>206-884-7554</phone>
    <email>nicole.rogers@seattlechildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Children's Hospital Alabama, University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Y Hathorne</last_name>
      <email>hhathorne@peds.uab.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Cross</last_name>
      <email>mary.cross@childrenscolorado.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer (Jenn) Gafford</last_name>
      <email>Jennifer.gafford@nemours.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandra Weisman</last_name>
      <email>a.weisman1@miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Nemours Children's Clinic - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Gibbs</last_name>
      <email>Kristen.Gibbs@nemours.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Bendy</last_name>
      <email>lbendy@iupui.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Teresi</last_name>
      <email>mary-teresi@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Scott</last_name>
      <email>lscott2@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Fowler</last_name>
      <email>Robert.fowler@childrens.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan, Michigan Medicine</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Kruse</last_name>
      <email>dmkruse@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Mulroy</last_name>
      <email>heather.mulroy@spectrumhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camerone Bey</last_name>
      <email>Camerone.bey@childrensmn.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Minnesota Cystic Fibrosis Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CF Trials Contact</last_name>
      <email>cftrials@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candy Schmoll</last_name>
      <email>cschmoll@cmh.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Hicks</last_name>
      <email>hickst@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cystic Fibrosis Center of Western New York</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Roach</last_name>
      <email>croach@upa.chob.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Liriano</last_name>
      <email>crl58@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Forell</last_name>
      <email>forellm@upstate.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Medical College at Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zachary Messer</last_name>
      <email>Zachary_Messer@nymc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Thornton</last_name>
      <email>Kelly.Thornton@cchmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Gilmore</last_name>
      <email>Diana.Gilmore@nationwidechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cystic Fibrosis Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CF Center Participant Contact</last_name>
      <email>cfresearchteam@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brendan Klein</last_name>
      <email>kleinb@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hershey Medical Center Pennsylvania State University</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane M Kitch</last_name>
      <email>dkitch@pennstatehealth.psu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Donnelly</last_name>
      <email>Donnellye4@email.chop.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Hartigan</last_name>
      <email>elizabeth.hartigan@chp.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern / Children's Health</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniyal Kamal</last_name>
      <email>Daniyal.Kamal@childrens.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Urbanek</last_name>
      <email>Heather.Urbanek@cookchildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katie Howe</last_name>
      <email>klhowe@texaschildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Primary Children's Cystic Fibrosis Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane B Vroom</last_name>
      <email>jane.vroom@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vermont Children's Hospital</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Sweet</last_name>
      <email>julie.sweet@uvmhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Altherr</last_name>
      <email>taa4n@virginia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon McNamara</last_name>
      <email>sharon.mcnamara@seattlechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Nelson</last_name>
      <email>mnelson@pediatrics.wisc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>Sonya Heltshe</investigator_full_name>
    <investigator_title>Associate Professor University of Washington</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>CF</keyword>
  <keyword>CFTR Modulator</keyword>
  <keyword>triple combination therapy</keyword>
  <keyword>elexacaftor</keyword>
  <keyword>tezacaftor</keyword>
  <keyword>ivacaftor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
    <mesh_term>Elexacaftor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

